Literature DB >> 1871695

Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine.

M M Bridgeman1, M Marsden, W MacNee, D C Flenley, A P Ryle.   

Abstract

N-acetylcysteine (600 mg/day) was given to patients by mouth for five days before bronchoscopy and bronchoalveolar lavage to determine whether N-acetylcysteine could increase the concentrations of the antioxidant reduced glutathione in plasma and bronchoalveolar lavage fluid. Bronchoalveolar lavage was performed 1-3 hours (group 2, n = 9) and 16-20 hours (group 3, n = 10) after the last dose of N-acetylcysteine and the values were compared with those in a control group receiving no N-acetylcysteine (group 1, n = 8). N-acetylcysteine was not detected in plasma or lavage fluid. Plasma concentrations of cysteine, the main metabolite of N-acetylcysteine and a precursor of reduced glutathione, were greater in the groups receiving treatment (groups 2 and 3) than in group 1. Cysteine concentrations in lavage fluid were similar in the three groups. Concentrations of reduced glutathione were greater in both plasma and lavage fluid in group 2 than in group 1. These data suggest that N-acetylcysteine given by mouth is rapidly deacetylated to cysteine, with resulting increases in the concentrations of cysteine in plasma and of reduced glutathione in plasma and the airways, which thus temporarily increase the antioxidant capacity of the lung.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1871695      PMCID: PMC1020912          DOI: 10.1136/thx.46.1.39

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  28 in total

1.  Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis.

Authors:  A M Cantin; R C Hubbard; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1989-02

2.  Mucus clearance from peripheral and central airways of asymptomatic cigarette smokers.

Authors:  J E Agnew; D Pavia; S W Clarke
Journal:  Bull Eur Physiopathol Respir       Date:  1986 May-Jun

3.  Protection against pulmonary O2 toxicity by N-acetylcysteine.

Authors:  P D Wagner; O Mathieu-Costello; D E Bebout; A T Gray; P D Natterson; C Glennow
Journal:  Eur Respir J       Date:  1989-02       Impact factor: 16.671

4.  Enhancement of intracellular glutathione protects endothelial cells against oxidant damage.

Authors:  M F Tsan; E H Danis; P J Del Vecchio; C L Rosano
Journal:  Biochem Biophys Res Commun       Date:  1985-02-28       Impact factor: 3.575

Review 5.  Alveolitis and collapse in the pathogenesis of pulmonary fibrosis.

Authors:  A Burkhardt
Journal:  Am Rev Respir Dis       Date:  1989-08

6.  Glutathione biosynthesis in the isolated perfused rat lung: utilization of extracellular glutathione.

Authors:  M Berggren; J Dawson; P Moldéus
Journal:  FEBS Lett       Date:  1984-10-15       Impact factor: 4.124

7.  Pharmacokinetics of N-acetylcysteine in man.

Authors:  L Borgström; B Kågedal; O Paulsen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Acetylcysteine: a drug with an interesting past and a fascinating future.

Authors:  I Ziment
Journal:  Respiration       Date:  1986       Impact factor: 3.580

9.  Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis.

Authors:  J B Rasmussen; C Glennow
Journal:  Eur Respir J       Date:  1988-04       Impact factor: 16.671

10.  Glutathione metabolism in the lung: inhibition of its synthesis leads to lamellar body and mitochondrial defects.

Authors:  J Mårtensson; A Jain; W Frayer; A Meister
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

View more
  33 in total

1.  Preventing exacerbations of chronic bronchitis and COPD.

Authors:  A Ekberg-Jansson; S Larsson; C G Löfdahl
Journal:  BMJ       Date:  2001-05-26

Review 2.  Antioxidants in neonatal lung disease.

Authors:  C H Fardy; M Silverman
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-09       Impact factor: 5.747

Review 3.  Oxidants/antioxidants in idiopathic pulmonary fibrosis.

Authors:  W MacNee; I Rahman
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

4.  Effect of N-acetyl cysteine on thiol levels.

Authors:  P N Dekhuijzen; C L Van Herwaarden
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

5.  Evaluation of albumin as a reference marker of dilution in bronchoalveolar lavage fluid from asthmatic and control subjects.

Authors:  C Ward; M Duddridge; J Fenwick; P V Gardiner; A Fleetwood; D J Hendrick; E H Walters
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

6.  Targeting c-Src Reverses Accelerated GPX-1 mRNA Decay in Chronic Obstructive Pulmonary Disease Airway Epithelial Cells.

Authors:  Abdoulaye J Dabo; Wendy Ezegbunam; Anne E Wyman; Jane Moon; Christopher Railwah; Alnardo Lora; Susan M Majka; Patrick Geraghty; Robert F Foronjy
Journal:  Am J Respir Cell Mol Biol       Date:  2020-05       Impact factor: 6.914

7.  Hydrogen Sulfide: a Novel Immunoinflammatory Regulator in Rheumatoid Arthritis.

Authors:  M Li; Jian-Chun Mao; Yi-Zhun Zhu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Chemoprevention by N-acetylcysteine of low-dose CT-induced murine lung tumorigenesis.

Authors:  Mark Steven Miller; Joseph E Moore; Matthew C Walb; Nancy D Kock; Albert Attia; Scott Isom; Jennifer E McBride; Michael T Munley
Journal:  Carcinogenesis       Date:  2012-10-26       Impact factor: 4.944

Review 9.  The role for N-acetylcysteine in the management of COPD.

Authors:  P N R Dekhuijzen; W J C van Beurden
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Targeted treatment in COPD: a multi-system approach for a multi-system disease.

Authors:  David Anderson; William Macnee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.